Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye

Source : https://doi.org/10.1080/10428194.2021.1873320

Abstract The emergence of highly effective multiple myeloma (MM) treatments may bring cure within reach and highlights the need for highly sensitive measurable residual disease (MRD) techniques to replace conventional response assessments. MRD is being incorporated as an endpoint in an increasing number of studies and had been repeatedly shown to be both a predictive marker of response to treatment and a prognostic marker for future relapse.